Women Are Leading the Way in Life Sciences

IDbyDNA Improves Analytical Performance and User Experience of Its Explify Platform and Respiratory and Urinary Pathogen ID/AMR Panels

With IDbyDNA’s latest software update to the Explify® Platform, labs can now take their NGS analysis of respiratory and urinary samples to the next level with improved sample management, strengthened user management controls, an enhanced total AMR picture and detection of the latest SARS-CoV-2 variants.

IDbyDNA Receives Second-Year Funding to Continue Participation in DARPA-funded DIGET Program

Awarded continued funding by MRIGlobal, IDbyDNA will continue to support DARPA’s “Detect it With Gene Editing Technologies” (DIGET) program focused on developing a next-generation, battlefield-tested device that delivers improved diagnostic testing of infectious disease threats.

MedCity News: The Diagnostic Dilemma of Co-Infections Requires Novel Solutions

Co-infections are common in patients with COVID-19 and are associated with a 3.3-fold higher risk of death. In a MedCity News article, Amy Hanson, PharmD, outlines how Precision Metagenomics offers better diagnostic testing to identify pathogens otherwise evading detection.

The Tech Tribune Awards IDbyDNA As One of the 2022 Best Tech Startups in Salt Lake City

Based on revenue potential, leadership team, product traction and competitive landscape, The Tech Tribune’s editorial team identified IDbyDNA as one of the very best tech startups across renowned tech hubs in the United States.

Utah Business Names Steven Flygare to the 40 Under 40 Professionals for 2022

Each year Utah Business celebrates 40 business professionals under the age of 40 who are working to evolve the state of Utah’s business landscape.

Utah Life Science Day Draws State Legislators and Industry Representatives to Capitol Hill

IDbyDNA showcased its contributions to the Utah life science industry, introducing its innovations to an audience of State legislators and industry leaders.

IDbyDNA is Making it Easier to Accurately Identify Pathogens that Cause Infectious Diseases

Utah Business recognizes IDbyDNA as a technology leader in infectious disease testing. Outlined in a feature article, they discuss how IDbyDNA’s Precision Metagenomics platform gives hope to identify and treat infectious diseases more accurately and precisely.

IDbyDNA Appoints Susan (Siw) Daniels as Vice President of R&D and Member of Executive Committee

Daniels fills a key leadership role at a critical time to drive the company’s R&D initiatives, team development and product portfolio expansion, taking IDbyDNA into the future of precision metagenomics with cutting edge breakthroughs in infectious disease testing.

IDbyDNA Expands Scientific Advisory Board with Infectious Disease, Sequencing & FDA Leaders

On the heels of its appointment of Next-Generation Sequencing (NGS) leader Neil Gunn as CEO, IDbyDNA announces the addition of several notable leaders to their Scientific Advisory Board, including Dr. Adrian Egli, Dr. Tamara V. Feldblyum, Dr. Karl Voelkerding, Dr. Christopher Woods, and Dr. Stephen Young.

Taking the Guesswork Out of Diagnostics

Next-Generation Sequencing and the Diagnosis of Disease

IDbyDNA Welcomes Biotech Top Talents Wendy Chang and Reza Anayat to Its Company Leadership Team

In support of their mission to become the Precision Metagenomics company in infectious disease testing and management, IDbyDNA has filled…

DARPA to Develop Hand-Held Disease Detection Device

Gunn named CEO at IDbyDNA

BioSpace Movers & Shakers

IDbyDNA Appoints Next-Gen Sequencing Executive Neil Gunn as New CEO

Infectious disease continues to be a leading cause of illness, morbidity and mortality around the world. In the fight to better understand all pathogens, including the SARS-CoV-2 lineage and its mutations, IDbyDNA, the pioneer in Precision Metagenomics, is focused on broadening availability for its Next-Generation Sequencing (NGS) targeted products. With that, the company has appointed NGS leader Neil Gunn as its new CEO to drive the next phase of growth.

IDbyDNA’s Metagenomics Suite Future-Proofs Labs for Coming Pathogen Crises

IDbyDNA Boosts Its Global Metagenomic Respiratory Pathogen/AMR Surveillance Solution to Now Offer Enhanced SARS-CoV-2 Variant Interpretation

How Variant Surveillance Could Drive a Sequencing Boom

CareDx CEO: ‘We’re Not Just a One-Trick Pony’

CareDx Adds Infectious Disease Focus to Transplant Diagnostics with IDbyDNA

Under 30 Alum Mammoth Biosciences To Develop Diagnostics For Department Of Defense

Mammoth, IDbyDNA Get DARPA Funds for CRISPR Diagnostics Development

DARPA to Fund CRISPR Diagnostics Using Mammoth, IDbyDNA Technologies

Genetic Engineering and Biotechnology News

The Future Is Now: How Metagenomics Could Affect Infectious Disease Diagnostics

The fight against Sars-CoV-2 in 2021: What’s next?

DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

IDbyDNA Announces Engagement in United States Defense Advanced Research Projects Agency (DARPA) Program to Detect Threats Using Gene Editing Technologies

CareDx, IDbyDNA Partner to Develop Infectious Disease Dx for Transplant Patients

CareDx Announces AlloID and Exclusive Partnership with IDbyDNA

IDbyDNA Receives Accreditation from College of American Pathologists (CAP)

Illumina, IDbyDNA Flesh Out Sequencing-Based Respiratory Tests

Startups Apply Powerful Genetic Sequencing Technique to Covid-19 Battle

Illumina and IDbyDNA Launch Test That May Find Next Epidemic

IDbyDNA and Illumina Launch New Rapid Test to Better Detect Respiratory Co-Infections and Identify Antibiotic-Resistant Pathogens

Healthcare Execs Discuss Working During a Pandemic

IDbyDNA Commercializing Explify Platform for Comprehensive Pathogen Detection and Surveillance

AWS and 1 Strategy Case Study: IDbyDNA and Application Migration, HIPAA Compliance, and DevOps Workflows

GenomeWeb Covers News of IDbyDNA’s Announcement this Week of SARS-CoV-2 Detection with the Gatot Soebroto Army Hospital in Indonesia

Metagenomics As a Tool To Diagnose and Understand COVID-19

IDbyDNA Chief Medical Officer Dr. Robert Schlaberg was just featured in an interview by Technology Networks, where he discusses how next-generation sequencing and metagenomics-based testing with the Explify Platform can address respiratory infections like SARS-CoV-2.

IDbyDNA to Help Indonesian Government Fight COVID-19 Pandemic

Metagenomics Innovator Delivers First NGS-Based SARS-CoV-2 Detection for Gatot Soebroto Army Hospital.

IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

IDbyDNA announces a global strategic partnership with Illumina to bring next-generation sequencing based workflows to the global microbiology market.

IDbyDNA Raises $20 Million in Series B Financing to Continue Advancements in Infectious Disease Diagnosis and Pathogen Identification

IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification, and interpretation of microorganisms and their role in human health, today announced the raise of $20 million in its Series B financing led by ARTIS Ventures and joined by Genesys Capital and others.

Novel Wuhan Coronavirus Detectable with IDbyDNA Explify Respiratory Test

IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification and interpretation of microorganisms and their role in human health, today announced that its currently available Explify Respiratory test can detect 2019-nCoV in addition to over 900 other viral, bacterial, fungal and parasitic pathogens.